Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0026367
DC FieldValue
dc.titleCrystal structure of thrombin in complex with s-variegin: Insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors
dc.contributor.authorKoh, C.Y.
dc.contributor.authorKumar, S.
dc.contributor.authorKazimirova, M.
dc.contributor.authorNuttall, P.A.
dc.contributor.authorRadhakrishnan, U.P.
dc.contributor.authorKim, S.
dc.contributor.authorJagadeeswaran, P.
dc.contributor.authorImamura, T.
dc.contributor.authorMizuguchi, J.
dc.contributor.authorIwanaga, S.
dc.contributor.authorSwaminathan, K.
dc.contributor.authorKini, R.
dc.date.accessioned2014-12-12T07:47:56Z
dc.date.available2014-12-12T07:47:56Z
dc.date.issued2011
dc.identifier.citationKoh, C.Y., Kumar, S., Kazimirova, M., Nuttall, P.A., Radhakrishnan, U.P., Kim, S., Jagadeeswaran, P., Imamura, T., Mizuguchi, J., Iwanaga, S., Swaminathan, K., Kini, R. (2011). Crystal structure of thrombin in complex with s-variegin: Insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors. PLoS ONE 6 (10) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0026367
dc.identifier.issn19326203
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/116279
dc.description.abstractThe inhibition of thrombin is one of the important treatments of pathological blood clot formation. Variegin, isolated from the tropical bont tick, is a novel molecule exhibiting a unique 'two-modes' inhibitory property on thrombin active site (competitive before cleavage, noncompetitive after cleavage). For the better understanding of its function, we have determined the crystal structure of the human α-thrombin:synthetic-variegin complex at 2.4 Å resolution. The structure reveals a new mechanism of thrombin inhibition by disrupting the charge relay system. Based on the structure, we have designed 17 variegin variants, differing in potency, kinetics and mechanism of inhibition. The most active variant is about 70 times more potent than the FDA-approved peptidic thrombin inhibitor, hirulog-1/bivalirudin. In vivo antithrombotic effects of the variegin variants correlate well with their in vitro affinities for thrombin. Our results encourage that variegin and the variants show strong potential for the development of tunable anticoagulants. © 2011 Koh et al.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1371/journal.pone.0026367
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentLIFE SCIENCES INSTITUTE
dc.contributor.departmentBIOLOGICAL SCIENCES
dc.description.doi10.1371/journal.pone.0026367
dc.description.sourcetitlePLoS ONE
dc.description.volume6
dc.description.issue10
dc.description.page-
dc.identifier.isiut000299081800015
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2011-crystal_structure_thrombin_complex_s-variegin-pub.pdf4.19 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

29
checked on Nov 23, 2020

WEB OF SCIENCETM
Citations

29
checked on Nov 23, 2020

Page view(s)

217
checked on Nov 21, 2020

Download(s)

5
checked on Nov 21, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.